Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States: an international network cohort study

Talita Duarte‐Salles, David Vizcaya, Andrea Pistillo, Paula Casajust, Anthony G. Sena, Lana Yin Hui Lai, Albert Prats‐Uribe, Waheed‐Ul‐Rahman Ahmed, Thamir M. Alshammari, Heba Alghoul, Osaid Alser, Edward Burn, Seng Chan You, Carlos Areia, Clair Blacketer, Scott L. DuVall, Thomas Falconer, Sergio Fernández‐Bertolín, Stephen Fortin, Asieh Golozar, Mengchun Gong, Eng Hooi Tan, Vojtech Huser, Pablo Iveli, Daniel R. Morales, Fredrik Nyberg, Jose Posada, Martina Recalde, Elena Roel, Lisa M. Schilling, Nigam H. Shah, Karishma Shah, Marc A. Suchard, Lin Zhang, Ying Zhang, Andrew E. Williams, Christian Reich, George Hripcsak, Peter Rijnbeek, Patrick Ryan, Kristin Kostka, Daniel Prieto‐AlhambramedRxiv 2020 · DOI

Abstract

While early COVID-19 research focused predominantly on adult populations, the clinical trajectory of the virus in children and adolescents remained less defined during the pandemic's first wave. This international network cohort study analyzed data from 55,270 children diagnosed with COVID-19 and nearly 2 million diagnosed with seasonal influenza across France, Germany, Spain, South Korea, and the United States. The study aimed to characterize demographics, comorbidities, symptoms, and outcomes. Findings indicate that while pediatric COVID-19 mortality is negligible, the risk of severe complications—including pneumonia, acute respiratory distress syndrome (ARDS), and multisystem inflammatory syndrome (MIS-C)—is significantly higher than that of influenza. Furthermore, the study reveals substantial international variation in inpatient management, highlighting a lack of standardized pediatric treatment protocols during the initial phase of the pandemic.

Introduction

During the initial stages of the COVID-19 pandemic, children were generally observed to experience milder illness than adults. However, high-quality, large-scale data to support clinical decision-making for pediatric patients was initially scarce, with most early evidence relying on small case series or localized reports. To address this gap, this study provides a comprehensive, international characterization of COVID-19 in children and adolescents, using seasonal influenza as a comparative benchmark to contextualize the severity and clinical presentation of the novel virus.

Methodology: The Power of Network Analytics

The researchers employed an international network cohort study design utilizing the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). This framework allows for the standardization of disparate electronic health records (EHRs) and insurance claims into a unified format. By standardizing 11 databases across five countries—the USA, France, Germany, Spain, and South Korea—the team could execute identical analytical protocols across diverse healthcare systems while maintaining patient privacy.

The study compared two primary cohorts:

  1. COVID-19 Cohort: Children and adolescents (<18 years) diagnosed or hospitalized with COVID-19 between January and June 2020.
  2. Influenza Cohort: Children and adolescents diagnosed with seasonal influenza during the 2017-2018 season.

Clinical Presentation and Differential Diagnosis

A key objective was identifying clinical markers that differentiate COVID-19 from influenza. While both viruses share common symptoms like fever and cough, COVID-19 patients exhibited significantly higher frequencies of specific symptoms that serve as critical clinical "red flags" for differential diagnosis:

  • Dyspnea (shortness of breath)
  • Anosmia (loss of smell)
  • Gastrointestinal symptoms (nausea, vomiting, diarrhea)

Additionally, the study noted that children requiring hospitalization for COVID-19 were more likely to have pre-existing comorbidities. Common clusters included asthma, obesity, congenital heart disease, and neurodevelopmental disorders, all of which were more prevalent among those hospitalized versus those only diagnosed in an outpatient setting.

Outcomes: Mortality vs. Morbidity

The data confirmed that 30-day mortality for pediatric COVID-19 was "undetectable" (fewer than five deaths per database) across all studied regions. This reinforces the understanding that death from COVID-19 is extremely rare in this age group.

However, the study highlights that COVID-19 carries a higher morbidity burden than seasonal influenza. Hospitalization rates for COVID-19 were 5 to 13 times higher than for influenza in several cohorts. Furthermore, severe complications were more prevalent in the COVID-19 group:

  • Pneumonia: The most common complication, affecting up to 20% of hospitalized children.
  • Acute Respiratory Distress Syndrome (ARDS): Consistently more frequent than in the influenza cohort.
  • Multisystem Inflammatory Syndrome in Children (MIS-C): While rare (<1%), MIS-C was almost exclusively associated with COVID-19, not influenza.

The Treatment Landscape

The study revealed significant heterogeneity in inpatient management strategies. In the absence of established pediatric guidelines during the first wave, treatment approaches varied drastically by country. For instance, the use of systemic corticosteroids ranged from 6.8% in South Korea to over 37% in certain US hospitals.

Clinicians frequently utilized adjunctive therapies rather than repurposed antivirals (like hydroxychloroquine or lopinavir-ritonavir, which saw <10% use). Common adjunctive treatments included:

  • Famotidine: Used in up to 28.1% of cases.
  • Antithrombotics: Including aspirin (up to 21.4%), heparin, and enoxaparin, reflecting clinical concerns regarding COVID-19-related coagulopathy.

Discussion and Limitations

This research provides a robust baseline for understanding pediatric COVID-19, yet the authors acknowledge several limitations. As a study based on real-world data (EHRs and claims), there is a risk of under-reporting symptoms compared to prospective clinical trials. Furthermore, the data represents the "first wave" of the pandemic; subsequent variants and the introduction of vaccines have likely altered the clinical landscape and management strategies.

Conclusion

While the negligible mortality rate is reassuring, the increased risk of severe respiratory complications and MIS-C compared to influenza underscores the importance of continued vigilance in pediatric COVID-19 management. The significant variation in medication use highlights the urgent need for evidence-based, standardized pediatric protocols. Future research must focus on the long-term effects of the virus (Long COVID) and the impact of emerging variants on the pediatric population.

Summary updated

Abstract

<b>Objectives</b> To characterize the demographics, comorbidities, symptoms, in-hospital treatments, and health outcomes among children/adolescents diagnosed or hospitalized with COVID-19. Secondly, to describe health outcomes amongst children/adolescents diagnosed with previous seasonal influenza. <b>Design</b> International network cohort. <b>Setting</b> Real-world data from European primary care records (France/Germany/Spain), South Korean claims and US claims and hospital databases. <b>Participants</b> Diagnosed and/or hospitalized children/adolescents with COVID-19 at age <18 between January and June 2020; diagnosed with influenza in 2017-2018. <b>Main outcome measures</b> Baseline demographics and comorbidities, symptoms, 30-day in-hospital treatments and outcomes including hospitalization, pneumonia, acute respiratory distress syndrome (ARDS), multi-system inflammatory syndrome (MIS-C), and death. <b>Results</b> A total of 55,270 children/adolescents diagnosed and 3,693 hospitalized with COVID-19 and 1,952,693 diagnosed with influenza were studied. Comorbidities including neurodevelopmental disorders, heart disease, and cancer were all more common among those hospitalized vs diagnosed with COVID-19. The most common COVID-19 symptom was fever. Dyspnea, bronchiolitis, anosmia and gastrointestinal symptoms were more common in COVID-19 than influenza. In-hospital treatments for COVID-19 included repurposed medications (<10%), and adjunctive therapies: systemic corticosteroids (6.8% to 37.6%), famotidine (9.0% to 28.1%), and antithrombotics such as aspirin (2.0% to 21.4%), heparin (2.2% to 18.1%), and enoxaparin (2.8% to 14.8%). Hospitalization was observed in 0.3% to 1.3% of the COVID-19 diagnosed cohort, with undetectable (N<5 per database) 30-day fatality. Thirty-day outcomes including pneumonia, ARDS, and MIS-C were more frequent in COVID-19 than influenza. <b>Conclusions</b> Despite negligible fatality, complications including pneumonia, ARDS and MIS-C were more frequent in children/adolescents with COVID-19 than with influenza. Dyspnea, anosmia and gastrointestinal symptoms could help differential diagnosis. A wide range of medications were used for the inpatient management of pediatric COVID-19.
BibTeX
@misc{duartesalles2020baseline,
  author = {Talita Duarte‐Salles and David Vizcaya and Andrea Pistillo and Paula Casajust and Anthony G. Sena and Lana Yin Hui Lai and Albert Prats‐Uribe and Waheed‐Ul‐Rahman Ahmed and Thamir M. Alshammari and Heba Alghoul and Osaid Alser and Edward Burn and Seng Chan You and Carlos Areia and Clair Blacketer and Scott L. DuVall and Thomas Falconer and Sergio Fernández‐Bertolín and Stephen Fortin and Asieh Golozar and Mengchun Gong and Eng Hooi Tan and Vojtech Huser and Pablo Iveli and Daniel R. Morales and Fredrik Nyberg and Jose Posada and Martina Recalde and Elena Roel and Lisa M. Schilling and Nigam H. Shah and Karishma Shah and Marc A. Suchard and Lin Zhang and Ying Zhang and Andrew E. Williams and Christian Reich and George Hripcsak and Peter Rijnbeek and Patrick Ryan and Kristin Kostka and Daniel Prieto‐Alhambra},
  title = {{Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States: an international network cohort study}},
  year = {2020},
  doi = {10.1101/2020.10.29.20222083},
  howpublished = {medRxiv},
}
Figure